Investigating how RNA methylation affects kidney cancer progression
RNA methylation as a novel effector of SETD2 in kidney cancer
['FUNDING_R21'] · MAYO CLINIC ROCHESTER · NIH-11061848
This study is looking at how changes in the SETD2 gene affect kidney cancer, specifically clear cell renal cell carcinoma, to find new ways to treat it better and help patients with personalized therapies.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11061848 on ClinicalTrials.gov |
What this research studies
This research focuses on clear cell renal cell carcinoma (ccRCC), a common and deadly form of kidney cancer. It aims to understand the role of the SETD2 gene, which is often mutated in ccRCC, and how these mutations impact RNA methylation and gene expression. By studying the mechanisms of SETD2 loss, the research seeks to identify new pathways that drive cancer growth and metastasis, potentially leading to more effective treatments. Patients may benefit from insights that could inform personalized therapies targeting these specific genetic alterations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with mutations in the SETD2 gene.
Not a fit: Patients with other types of kidney cancer or those without actionable mutations in SETD2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for kidney cancer that are tailored to the genetic profile of individual tumors.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic alterations in cancer, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROBERTSON, KEITH D — MAYO CLINIC ROCHESTER
- Study coordinator: ROBERTSON, KEITH D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancer Cause